New drug cocktail hopes to tackle advanced colon cancer

NCT ID NCT07621159

Not yet recruiting Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HDM2017 combined with standard treatment (fruquintinib) in 120 people with advanced colorectal cancer that has spread. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have tried other treatments and have a life expectancy of at least 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM2017 combined with fruquintinib
What this could lead to: If successful, this could lead to a new treatment option for advanced colorectal cancer that may shrink tumors or slow disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 120 participants, so results may not confirm effectiveness. Side effects from the drug combination are unknown and could be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Peking University Cancer Hospital

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.